trastuzumab-anns 150 MG Injection

RxCUI: 2257297
RxNorm name: trastuzumab-anns 150 MG Injection
Display name: trastuzumab-anns 150 MG Injection
Full name: trastuzumab-anns 150 MG Injection
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:10

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761073	Kanjinti	trastuzumab-anns	351(k) Biosimilar	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Kanjinti	TRASTUZUMAB-ANNS	Amgen, Inc	9a94f5b2-b84e-4987-8ea1-c4346db5a5fa	2026-06-23	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2257297

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
9a94f5b2-b84e-4987-8ea1-c4346db5a5fa	trastuzumab-anns 150 MG Injection	PSN	22	These highlights do not include all the information needed to use KANJINTI safely and effectively. See full prescribing information for KANJINTI. KANJINTI ® (trastuzumab-anns) for injection, for intravenous use Initial U.S. Approval: 2019 KANJINTI (trastuzumab-anns) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differe	20260310
9a94f5b2-b84e-4987-8ea1-c4346db5a5fa	trastuzumab-anns 150 MG Injection	SCD	22	These highlights do not include all the information needed to use KANJINTI safely and effectively. See full prescribing information for KANJINTI. KANJINTI ® (trastuzumab-anns) for injection, for intravenous use Initial U.S. Approval: 2019 KANJINTI (trastuzumab-anns) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differe	20260310